Use access key #2 to skip to page content.
$69.08 -0.55 (-0.79%)
5/16/2008 4:00 PM

Genzyme Corp (GENZ)

CAPS Rating:
*****

A biotechnology company dedicated to making an impact on the lives of people with serious diseases. Its product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, and diagnostic and predictive testing.

View All Commentary (GENZ)

Recs

0

Avatar ResearchLover (98.29) Submitted: 4/23/08 3:42 PM : Outperform Start Price: $73.12 GENZ Score: -8.99

I like the chart with rising MAs, earnings just announced showing growth, and the forward PE of 20 at this price. Plus they could spin off or sell off any one of their six segments if business development at another company justifies a synergistic valuation.

Report this Post Replies: 0 | Reply

Featured Broker Partners